Published in Mayo Clin Proc on August 01, 2006
Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med (2007) 9.83
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med (2012) 1.94
Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int (2011) 1.77
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res (2011) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int (2008) 1.68
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int (2008) 1.65
Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int (2007) 1.51
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int (2009) 1.50
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med (2013) 1.49
Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int (2009) 1.47
Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res (2008) 1.47
The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol (2010) 1.44
GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int (2011) 1.43
Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice. Osteoporos Int (2012) 1.42
Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int (2009) 1.39
Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int (2007) 1.33
Denosumab. Nat Rev Drug Discov (2010) 1.31
Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care (2009) 1.31
Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int (2011) 1.26
Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med (2008) 1.25
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int (2008) 1.24
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc (2010) 1.16
Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA). Osteoporos Int (2011) 1.15
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int (2009) 1.14
Adherence to treatment of osteoporosis: a need for study. Osteoporos Int (2007) 1.13
Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practice. Trials (2009) 1.12
Targeted intervention reduces refracture rates in patients with incident non-vertebral osteoporotic fractures: a 4-year prospective controlled study. Osteoporos Int (2010) 1.12
A guide to improving the care of patients with fragility fractures. Geriatr Orthop Surg Rehabil (2011) 1.12
Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction (2008) 1.12
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab (2007) 1.11
The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int (2011) 1.09
Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician (2008) 1.08
Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int (2010) 1.07
Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int (2011) 1.06
Adherence and profile of non-persistence in patients treated for osteoporosis--a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int (2010) 1.05
Comment on Cassell and Clapperton: A decreasing trend in fall-related hip fracture incidence in Victoria, Australia. Osteoporos Int (2013) 1.04
Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int (2008) 1.03
Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int (2008) 1.02
Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int (2013) 1.02
Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int (2008) 1.01
A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc (2006) 1.00
Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care (2011) 1.00
Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int (2011) 0.99
The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord (2007) 0.99
The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab (2010) 0.99
Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int (2007) 0.99
A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (2011) 0.98
Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective. J Bone Miner Res (2008) 0.98
Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study. BMC Musculoskelet Disord (2011) 0.98
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int (2010) 0.98
Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials. Osteoporos Int (2009) 0.97
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int (2010) 0.97
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging (2008) 0.96
Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int (2008) 0.95
Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int (2012) 0.95
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int (2014) 0.94
Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int (2015) 0.94
Hip fractures in users of first- vs. second-generation bisphosphonates. Osteoporos Int (2007) 0.94
Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manag Care (2009) 0.94
Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence (2009) 0.94
Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord (2014) 0.94
Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol (2009) 0.93
Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporos Int (2011) 0.92
Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management. Drug Healthc Patient Saf (2010) 0.92
Adherence to alendronate in male veterans. Osteoporos Int (2007) 0.92
Osteoporosis care at risk in the United States. Osteoporos Int (2008) 0.91
Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int (2009) 0.91
Insights from the conduct of a device trial in older persons: low magnitude mechanical stimulation for musculoskeletal health. Clin Trials (2010) 0.90
Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int (2013) 0.90
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol (2008) 0.90
Diagnosis and management of osteoporosis in the older senior. Clin Interv Aging (2009) 0.90
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int (2008) 0.88
Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging (2010) 0.88
Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis (2009) 0.88
Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts. Br J Pharmacol (2010) 0.87
Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence. Osteoporos Int (2012) 0.87
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int (2009) 0.87
Osteoporosis medication profile preference: results from the PREFER-US study. Health Expect (2007) 0.87
Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int (2008) 0.87
Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates. Osteoporos Int (2010) 0.87
Challenges in implementing and maintaining osteoporosis therapy. Int J Womens Health (2014) 0.86
Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study. J Osteoporos (2011) 0.86
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Evaluation of persistence and adherence to teriparatide treatment in patients affected by severe osteoporosis (PATT): a multicenter observational real life study. Clin Cases Miner Bone Metab (2013) 0.86
Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int (2010) 0.86
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int (2009) 0.85
Patients reject the concept of fragility fracture--a new understanding based on fracture patients' communication. Osteoporos Int (2012) 0.85
Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. Core Evid (2010) 0.85
Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study. Osteoporos Int (2014) 0.85
Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int (2011) 0.84
Adherence to anti-osteoporotic therapies: role and determinants of "spot therapy". Osteoporos Int (2013) 0.83
Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int (2009) 0.83
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem (2002) 4.52
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med (2012) 3.34
Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell (2009) 3.16
Postmenopausal Osteoporosis. N Engl J Med (2016) 3.04
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev (2005) 3.01
The prevalence of pituitary adenomas: a systematic review. Cancer (2004) 2.98
Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom (2008) 2.87
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone (2008) 2.53
Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab (2009) 2.31
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology (2008) 2.09
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc (2006) 1.96
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity (Silver Spring) (2010) 1.93
Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab (2013) 1.88
Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res (2012) 1.84
Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab (2010) 1.80
The 2011 Dietary Reference Intakes for Calcium and Vitamin D: what dietetics practitioners need to know. J Am Diet Assoc (2011) 1.80
Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med (2012) 1.80
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med (2012) 1.79
Congenic strains of mice for verification and genetic decomposition of quantitative trait loci for femoral bone mineral density. J Bone Miner Res (2003) 1.78
Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res (2004) 1.76
Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc (2005) 1.74
Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res (2002) 1.73
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol (2010) 1.72
Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res (2005) 1.70
Mechanical stimulation of mesenchymal stem cell proliferation and differentiation promotes osteogenesis while preventing dietary-induced obesity. J Bone Miner Res (2009) 1.67
Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res (2010) 1.66
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
Moderate alcohol intake lowers biochemical markers of bone turnover in postmenopausal women. Menopause (2012) 1.63
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Marrow fat and bone--new perspectives. J Clin Endocrinol Metab (2013) 1.60
Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell (2013) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res (2002) 1.58
Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology (2005) 1.58
Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. Cancer Epidemiol Biomarkers Prev (2002) 1.57
What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Ann N Y Acad Sci (2014) 1.54
Bicc1 is a genetic determinant of osteoblastogenesis and bone mineral density. J Clin Invest (2014) 1.53
Mapping quantitative trait loci for vertebral trabecular bone volume fraction and microarchitecture in mice. J Bone Miner Res (2003) 1.52
PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem (2009) 1.51
PPARG by dietary fat interaction influences bone mass in mice and humans. J Bone Miner Res (2008) 1.50
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med (2004) 1.48
A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci U S A (2010) 1.46
Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab (2013) 1.45
Bone density in ambulatory and immobile children. J Clin Densitom (2002) 1.43
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
Genetic effects for femoral biomechanics, structure, and density in C57BL/6J and C3H/HeJ inbred mouse strains. J Bone Miner Res (2003) 1.37
The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol (2006) 1.37
Determinants of bone mineral density in obese premenopausal women. Bone (2010) 1.36
Osteonecrosis of the jaw: more research needed. J Bone Miner Res (2006) 1.36
Fat targets for skeletal health. Nat Rev Rheumatol (2009) 1.36
Bone marrow changes in adolescent girls with anorexia nervosa. J Bone Miner Res (2010) 1.35
Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res (2005) 1.34
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J Bone Miner Res (2002) 1.28
Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology (2008) 1.26
Genetic dissection of mouse distal chromosome 1 reveals three linked BMD QTLs with sex-dependent regulation of bone phenotypes. J Bone Miner Res (2007) 1.26
Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr (2002) 1.25
Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone (2006) 1.25
Altered metabolism and lipodystrophy in the early B-cell factor 1-deficient mouse. Endocrinology (2010) 1.24
Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med (2006) 1.23
Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J (2008) 1.23
Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res (2005) 1.23
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. Eur J Endocrinol (2012) 1.21
Growth hormone regulates the balance between bone formation and bone marrow adiposity. J Bone Miner Res (2010) 1.20
Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev (2010) 1.19
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. Endocrinology (2013) 1.18
Young women with cold-activated brown adipose tissue have higher bone mineral density and lower Pref-1 than women without brown adipose tissue: a study in women with anorexia nervosa, women recovered from anorexia nervosa, and normal-weight women. J Clin Endocrinol Metab (2012) 1.18
Preadipocyte factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosa. J Clin Endocrinol Metab (2009) 1.18
Quantitative trait loci that determine BMD in C57BL/6J and 129S1/SvImJ inbred mice. J Bone Miner Res (2005) 1.17
Postnatal growth and bone mass in mice with IGF-I haploinsufficiency. Bone (2006) 1.16
Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. J Clin Endocrinol Metab (2013) 1.16
Evaluation and management of osteoporosis following hospitalization for low-impact fracture. J Gen Intern Med (2003) 1.16
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab (2002) 1.14
The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene (2005) 1.12
Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1. J Bone Miner Res (2010) 1.12
Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab (2011) 1.11
PERK eIF2alpha kinase regulates neonatal growth by controlling the expression of circulating insulin-like growth factor-I derived from the liver. Endocrinology (2003) 1.11
Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. J Bone Miner Res (2012) 1.11
Quantitative trait loci for BMD in an SM/J by NZB/BlNJ intercross population and identification of Trps1 as a probable candidate gene. J Bone Miner Res (2008) 1.10
A missense mutation in the mouse Col2a1 gene causes spondyloepiphyseal dysplasia congenita, hearing loss, and retinoschisis. J Bone Miner Res (2003) 1.09
Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. Medscape J Med (2008) 1.08
Impact of seafood and fruit consumption on bone mineral density. Maturitas (2006) 1.07
Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med (2003) 1.07
From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) (2003) 1.07
Cost savings in migraine associated with less chest pain on new triptan therapy. Am J Manag Care (2002) 1.07
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res (2005) 1.06